Mapmygenome, an Indian personal genomics and precision health company, has completed its acquisition of dnaPower, a Vancouver company that sells DNA-based health, nutrition, fitness and longevity reports. The deal was announced on October 21, 2026, from Vancouver.
Financial terms were not disclosed, and the announcement did not say how much of dnaPower Mapmygenome bought or how the purchase was paid for. It also did not say whether dnaPower founder Lois Nahirney will keep running the business, or what role she will take inside the group.
dnaPower will be combined with Microbiome Insights, the Vancouver sequencing lab Mapmygenome bought in 2025, to create one North American platform for DNA, gut microbiome, pharmacogenetic and longevity testing in Canada and the United States. The companies said they will run a Vancouver processing hub under CAP-accredited and ISO-certified procedures.
What dnaPower built
dnaPower was founded in 2008 and is run by its founder and chief executive, Dr. Lois Nahirney. It sells genetic tests and reports on health, nutrition, fitness, methylation and longevity to consumers and to practitioners who use them with their own clients.
Mapmygenome described the company as a pioneer in personal genomics and said the deal brings it dnaPower's consumer reach and commercial momentum. dnaPower did not disclose its revenue, customer numbers or headcount.
"Joining Mapmygenome unlocks an extraordinary growth chapter for dnaPower," Nahirney said. She said backing from a company with large laboratory infrastructure would let dnaPower scale across North America.
“Acquiring dnaPower is a pivotal step in scaling our North American operations.”
Why Mapmygenome is buying
Mapmygenome, founded and led by chief executive Anu Acharya, built its business in India. It now describes itself as a global company combining AI-driven multi-omics analysis with CAP-accredited clinical labs.
In May 2025 it bought Microbiome Insights, which it said gave it a CAP-accredited Canadian laboratory and the intellectual property behind its microbiome sequencing, while Microbiome Insights kept working as a contract research organisation for research clients. Buying dnaPower adds a consumer-facing brand in the same city.
Microbiome Insights, led by chief executive Malcolm Kendall, had completed more than 1,000 studies for more than 600 clients when Mapmygenome bought it, according to Entrepreneur India. The lab handles DNA, microbiome and multi-omics sequencing, analytics and bioinformatics, and will process the samples that dnaPower's customers send in.
"Acquiring dnaPower is a pivotal step in scaling our North American operations," Acharya said. She said pairing dnaPower with Mapmygenome's laboratories and AI would let the group lead in microbiome, longevity and precision health testing.
The combined offer is meant to cover gut microbiome profiling by shotgun metagenomic sequencing, epigenetic biological age panels, whole-genome and exome sequencing, pharmacogenetics, DNA wellness panels and methylation testing.
Mapmygenome also said it will use the combined business to launch new commercial offerings in healthy ageing, gut profiling and epigenetic assessment, drawing on its multi-omics analytics and clinical laboratory capabilities. It did not give a timetable or prices for those products.
The founders and the funding
Neither company disclosed dnaPower's funding history, and no outside investors in dnaPower were named. Nahirney is identified as the company's founder.
When it bought Microbiome Insights, Mapmygenome said the deal was part of a strategy of growth through targeted acquisitions leading up to a planned listing on the Indian market. It has not given an update on that plan in the dnaPower announcement.
A crowded market for longevity tests
Consumer DNA and longevity testing has become crowded, with companies selling biological age scores, gut health reports and nutrition advice directly to customers and through clinics. Smaller brands often rely on outside labs, which squeezes their margins.
Mapmygenome's approach is to own both ends: its laboratories process samples, and brands such as dnaPower sell the reports. Pulse 2.0 noted that dnaPower gains access to Mapmygenome's lab infrastructure, technology and research and development as part of the deal.
The companies did not say whether dnaPower's products or brand will change after the acquisition.
